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Abstract 
People frequently live for many years with multiple chronic conditions (multimorbidity) that impair 
health outcomes and are expensive to manage. Multimorbidity has been shown to reduce quality of 
life and increase mortality. People with multimorbidity also rely more heavily on health and care 
services and have poorer work outcomes. Musculoskeletal disorders (MSDs) are ubiquitous in 
multimorbidity because of their high prevalence, shared risk factors, and shared pathogenic 
processes amongst other long-term conditions. Additionally, these conditions significantly contribute 
to the total impact of multimorbidity having been shown to reduce quality of life, increase work 
disability, and increase treatment burden and healthcare costs. For people living with 
multimorbidity, MSDs could impair the ability to cope and maintain health and independence, 
leading to precipitous physical and social decline. Recognition, by health professionals, policymakers, 
non-profit organisations, and research funders, of the impact of musculoskeletal health on 
multimorbidity is essential when planning support for people living with multimorbidity. 
Key words 
Multi-morbidity, Co-morbidity, Musculoskeletal, Arthritis, Osteoarthritis, Osteoporosis, Back pain, 
Functional Limitations, Management, Self-management, Prevalence, Policy.   
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Introduction 
The co-existence of at least two different long-term health conditions in the same individual has 
been variously defined in the literature as “multimorbidity” or “comorbidity” but with a lack of clear 
consensus about the use of these definitions.(1) The term ‘comorbidity’ is generally used for any 
additional health condition(s) occurring at the same time in the same individual to a previously-
defined index condition. For the purpose of this review, multimorbidity has been defined as any 
individual having two or more long-term conditions. For example, a person with concomitant 
diabetes and asthma has ‘multimorbidity’. Importantly, these terms include long-term mental, as 
well as physical component health conditions. However defined, there is evidence that the 
prevalence of people living with two or more long-term health conditions, is rising.(2) 
Musculoskeletal disorders (MSDs) appear to form a principal component of certain multimorbidity 
clusters(3) and are common in multimorbidity.(4,5) Certainly, a substantial proportion of people with 
MSDs now live with multimorbidity.(4,6) There are many MSDs, including: inflammatory rheumatic 
diseases, such as rheumatoid arthritis and spondyloarthritis; degenerative conditions, such as 
osteoarthritis; fragility conditions, such as osteoporosis; and regional pain syndromes, such as low 
back pain, neck pain and the widespread pain condition, fibromyalgia. MSDs are common throughout 
the life course but become increasingly common at older ages (in particular, low back pain and 
osteoarthritis).  
This review will set out what we know about the importance of MSDs in multimorbidity, informed by 
the work done by the leading UK charity for people with MSDs, Arthritis Research UK,(7) and a search 
of the literature. Our aim is to highlight the importance of multimorbidity and musculoskeletal 
disease to healthcare commissioners, healthcare providers, government and policy makers as well as 
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non-profit organisations in order to ensure that the complex needs of this growing group of people 
are appropriately addressed and to inform the research agenda.  
The importance of musculoskeletal conditions in multimorbidity 
Musculoskeletal disorders are markedly heterogeneous, ranging from highly disabling but fortunately 
less common conditions such as rheumatoid arthritis, ankylosing spondylitis and systemic lupus 
through to considerably more common but generally less disabling conditions such as low back pain 
and osteoarthritis. At older ages, osteoporosis also causes a substantial burden by increasing the risk 
of low-trauma fractures.(8)  
In addition, multimorbidity and comorbidity are defined with inconsistent criteria in the literature. 
Multimorbidity has been described as having co-occurring long term conditions; co-occurring long 
term conditions or acute conditions; or co-occurring long term conditions, acute conditions or 
health-related risk factors.(9,10) Studies may also use completely different checklists of specific 
diseases or health-related risk factors. These difficulties with classification cause a particular problem 
when trying to define the prevalence of multimorbidity.(11) 
As a consequence, it is also difficult to define the impact of MSDs in multimorbidity. Furthermore, 
impact can be measured in a number of different ways: on an individual; on an individual’s 
family/carers; on society; on healthcare resources; and on costs. Complete data are not available for 
each of the MSDs in each of these domains, nor indeed for every definition of multimorbidity, 
making the overall picture patchy. Nevertheless, the following sections will outline what we currently 
know about the relative importance of MSDs in multimorbidity. 
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Musculoskeletal diseases are a pervasive component of multimorbidity  
Multimorbidity can occur for a number of reasons.(12) Chiefly, the existing high prevalence of certain 
conditions mean that the likelihood of co-occurrence together in one person, by chance alone, is 
high, particularly for conditions which become more common with increasing age. For example, 
osteoarthritis and asthma may commonly co-occur but have no known etiological association. 
Shared risk factors between conditions can also increase the likelihood of clustering. For example, 
obesity increases the risk of both osteoarthritis and type 2 diabetes.(13,14) Finally, sometimes a 
pathogenic link between conditions means the risk of another developing is greater. For example, 
there is a known causal pathway between rheumatoid arthritis and cardiovascular disease.(15) Below 
we will outline how these three mechanisms of multimorbidity, relate to the prevalence of MSDs in 
multimorbidity. 
MSDs and multimorbidity are both highly prevalent  
Longitudinal evidence from various countries suggests that the number of people with 
multimorbidity is growing.(2,16,17) In the European Union, there is an estimated 50 million people 
with multimorbidity and this number is expected to grow as the population ages.(18) According to 
one estimate in England, by 2018, there will be 2.9 million people living with multimorbidity, as 
compared with 1.9 million in 2008.(2)  
Worldwide, prevalence figures for multimorbidity vary greatly depending on the type and the 
number of conditions included.(19,20) In UK primary care, 16% of all adults were defined with 
multimorbidity using a total of 17 conditions then included in Quality and Outcomes Framework 
(QoF), including: asthma, atrial fibrillation, cancer, coronary heart disease, chronic kidney disease, 
chronic obstructive airways disease, dementia, depression, diabetes, epilepsy, heart failure, 
hypertension, learning disability, mental health problem (psychosis, schizophrenia, or bipolar 
affective disorder), obesity, stroke, and thyroid disease. However, this definition did not include any 
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MSDs and therefore was likely to vastly underestimate the true prevalence of multimorbidity in 
primary care (QoF has since been updated to include rheumatoid arthritis and osteoporosis).  
Unsurprisingly, the estimated prevalence increased to 58% when a broader list of long-term 
conditions was used which included arthritis, osteoporosis, gout, and low back pain.(11)  
Due to their high prevalence, musculoskeletal disorders have higher odds of co-occurring with other 
long term conditions, and therefore forming a component disorder in multimorbidity. In the 
European Union, chronic musculoskeletal pain is experienced by an estimated 100 million 
people.(21) Back pain, for example, has a mean estimated 1-year prevalence of 38%, worldwide.(22) 
Across the UK, an estimated 8.75 million people have sought treatment for osteoarthritis, the 
equivalent to a third of all people over 45 years of age.(23) Additionally, an estimated 1 in 2 women 
aged over 50 years and 1 in 5 men will sustain a low-trauma fracture as a result of osteoporosis(24–
26) with the situation set to worsen with demographic changes.(8) The endemic high prevalence of 
these conditions is one key factor in explaining their frequent contribution to multimorbidity.  
MSDs and multimorbidity share important risk factors 
Many important risk factors for common MSDs show striking overlap with risk factors for 
multimorbidity, even where the definition of multimorbidity has not included MSDs.  For example, 
age and female gender are two of the most important non-modifiable risk factors for MSDs (though 
this may not be true for individual conditions).(27) Likewise, there is a greater risk of multimorbidity 
among women as compared with men.(28,29) Unsurprisingly multimorbidity is also associated with 
increasing age;(11,28) the majority of people aged over 65 years are affected by multimorbidity.(30) 
For example, in Scotland, the estimated prevalence of multimorbidity was 64.9% amongst those aged 
65-84 years and these rates increased to 81.5% among those aged 85 years or over.(30)  
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Modifiable risk factors such as physical inactivity and obesity are importantly associated with 
osteoarthritis and other regional pain syndromes, including low back pain.(13) Smoking is the main 
modifiable risk factor for inflammatory arthritis and lifestyle risk factors for osteoporosis include 
smoking, poor nutrition and low physical activity.(31) Multimorbidity has a similarly clear association 
with obesity,(32–36) and, while evidence about other modifiable risk factors for multimorbidity is 
scarce, there are parallels with those for MSDs. For instance, smoking,(34) physical activity in elderly 
males,(37) and nutrition(38) have been linked to multimorbidity in recent publications.  
Social deprivation has been found to be associated with an increased likelihood of reporting  chronic 
painful conditions, including arthritis and back pain.(39) For example, among English people of 
working age (45-64 years), the reported prevalence of arthritis was found to be more than double 
(21.5%) that observed in the least deprived areas (10.6%).(40) Multimorbidity also shows a strong 
association with social deprivation;(11,20,29) people in the most deprived areas develop 
multimorbidity on average 10–15 years earlier than those living in the least deprived areas.(30) In 
particular, a higher risk of multimorbidity including a mental health condition has been 
demonstrated among people in the most deprived areas (11% versus 5.9% respectively).(30)  
MSDs and long-term conditions may cause and exacerbate one another 
Lastly, sometimes there are direct causal relationships between MSDs and other long term 
conditions. For example, people with rheumatoid arthritis are at increased risk of developing several 
comorbid diseases including cardiovascular disease and osteoporosis because of shared aetiological 
pathways. It has been estimated that one in 20 (6%) people with rheumatoid arthritis develop 
cardiovascular disease,(41,42) and osteoporosis.(43)  
People with poor musculoskeletal health also carry a greater burden of mental health problems. 
MSDs, like many long term conditions, are associated with an increased risk of mood, anxiety and 
substance use disorders. The association is even stronger in those with back pain or 
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fibromyalgia.(44,45) Musculoskeletal disorders and mental health have a complex and reciprocal 
relationship, each exacerbating, or potentially causing, the other. Living with persistent pain can lead 
to depression and anxiety. Conversely, psychological distress and depression worsen the experience 
and reporting of pain.(46) A cycle can therefore develop, with ever-worsening pain and low mood 
leading to social withdrawal and isolation. People with mental health conditions may also delay 
seeking treatment, and clinicians may underestimate physical symptoms, attributing these to an 
individual’s mental health condition.(47)  
MSDs and multimorbidity frequently occur together 
A combination of the factors discussed above explains the high prevalence of musculoskeletal 
disorders found alongside other long-term conditions as part of multimorbidity. For example, it has 
been shown that among English primary care patients, over 45 years of age, reporting living with a 
major long-term condition, almost a third also have a musculoskeletal condition.(40) Moreover, 
among those aged > 65 years, almost half of those with a heart, lung or mental health problem also 
had an MSD (see figure 1.).(40) In the most deprived populations, painful conditions, such as 
osteoarthritis and back pain, are the most common multimorbidity among those already living with 
heart disease, diabetes, chronic obstructive pulmonary disease (COPD) or cancer.(30)  
 
 
 
 
 
10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Prevalence of musculoskeletal disorders among English people a) aged 45 years and over 
and b) aged 65 years and over, reporting other long-term conditions.(40) 
The converse is also true: people with an MSD have been shown to be more likely to have at least 
one other long-term condition. For example, according to the results of one study, four out of five 
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people with osteoarthritis had at least one other long-term condition such as hypertension or 
cardiovascular disease.(6)  
In order to visualise the relationship between MSDs and multimorbidity, and recognising the varying 
multimorbidity criteria used in the literature, a recent cross-sectional study used three definitions to 
define the prevalence of multimorbidity in working-age Australians. Two multimorbidity thresholds 
(i.e. minimum of 2+ or 3+ conditions) were compared, as well as three definitions of multimorbidity 
from three sources: a survey-based definition from the Australian National Health Survey; a policy-
based definition from the Australian National Health Priority Areas; and a research definition from a 
well-cited systematic review. They found that irrespective of how multimorbidity is defined, 
musculoskeletal disorders are a near-ubiquitous feature of multimorbidity (see figure 2.).(4) 
 
Figure 2: Overlap between Australian populations with musculoskeletal disorders and multimorbidity 
as defined by each definition and threshold. A total working-age sample population; B sub-sample 
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with at least one condition; C sub-sample with multimorbidity; D sub-sample with any 
musculoskeletal condition; E musculoskeletal sub-sample considered multimorbid. Figure has been 
reproduced, with permissions, from Lowe et al (2017).(4)   
Musculoskeletal diseases exacerbate the impact of multimorbidity 
Having seen that musculoskeletal disorders are highly prevalent among people with multimorbidity, 
it is also important to explore the contribution of MSDs to the total impact of multimorbidity. The 
personal, societal and economic impact of MSDs and multimorbidity are outlined below.  
MSDs contribute to the health-burden in multimorbidity 
Worldwide, musculoskeletal disorders are the third largest cause of disability adjusted life years 
(DALYs) and the largest single cause of years lived with disability (YLD).(48) Pain is a very common 
feature of most MSDs. For example, 78% of people with arthritis surveyed by Arthritis Research UK 
reported that they experience pain most days, with 57% experiencing pain every day.(49) Activities 
of daily living (ADLs or instrumental ADLs) such as bathing, dressing, getting out of bed or a chair, 
completing housework, preparing meals and shopping are frequently affected by the pain, along with 
other common MSD symptoms, such as stiffness, restricted mobility and impaired physical 
functioning.(50) People often need to make adaptations to their home to enable them to cope. 
Moreover, symptoms of MSDs, particularly those with an inflammatory cause, tend to fluctuate in 
severity over time so that their effects are unpredictable.(51–53) The pain, distress and functional 
limitations caused by MSDs greatly reduce independence and quality of life, and impair an 
individual’s ability to participate in family, social and working life.(31) Arthritis and back pain, in 
particular, are amongst the most common causes of reduced health-related quality of life in the 
individual and, because of their high prevalence, the wider population.(29,46) There is also a 
significant impact on financial health. Work impairment and increased personal cost mean that 73% 
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of people with severe arthritis are struggling with their financial stability relative to their income, as 
compared with only 6% of those without functional limitations.(49) 
People with multimorbidity are similarly less able to perform everyday tasks due to functional 
decline.(54) People with multimorbidity have worsened quality of life and health outcomes than 
those with one index condition.(55) For instance, in a range of index diseases, the presence of a 
comorbidity is consistently shown to increase mortality rates when compared to the index disease 
alone.(55) Morbidities tend to accrue in individuals, for instance, as the number of physical 
comorbidities increase, so too does the likelihood of developing a mental health problem.(30) This 
accumulation of pathologies contributes to the complex and numerous needs of people with 
multimorbidity. 
Self-reported Quality of Life (QoL) scores can be used to understand the personal impact of long-
term conditions, and can help to show the contribution of specific diseases to poor health in 
multimorbidity. In a national English survey, people living with one or more non-musculoskeletal 
long-term conditions reported substantially poorer quality of life than those without a long-term 
condition (QoL score 0.79 vs 0.90, respectively). However, quality of life was even more significantly 
reduced among those who had arthritis or back pain as part of their multimorbidity (QoL score 0.71). 
Notably, the impact of the musculoskeletal disorders was significant enough that living with arthritis 
or back pain resulted in impaired quality of life irrespective of whether arthritis or back pain were the 
only condition (QoL score 0.68) or were one among multimorbidity (QoL score 0.71) (see figure 3.). 
This suggests that MSDs disproportionately reduce quality of life in multimorbidity, compared to 
other long-term conditions.(40)  
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Figure 3: Average Quality of Life scores for people aged 45 years and over who live with long-term 
conditions. 
MSDs contribute to the treatment burden in multimorbidity and can impair self-
management, leading to health and social decline 
Despite the proven effectiveness of many individual therapies commonly used in long term medical 
conditions, each additional therapy carries a ‘treatment burden.’ Treatment burden is a concept that 
encapsulates the physical effects of treatment, financial losses, and the psychosocial effects of time 
demands and dependence on others for assistance.(56) Quite obviously, the effects of treatment 
burden increase in a person receiving multiple treatments for multiple health problems. For 
example, a review of five UK disease-based clinical guidelines concluded that implementation of all 
individual disease best practice recommendations for a person with multimorbidity would encourage 
polypharmacy.(57) Recent clinical guidance recommends a person-centred approach to 
multimorbidity, prioritising treatments that improve quality of life while minimising treatment 
burden.(58) 
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The existence of any one MSD can contribute significantly to the overall number of treatments a 
person may be receiving. The management of MSDs aims to improve quality of life by reducing joint 
pain and stiffness, limiting progression of joint damage and maintaining or restoring functional 
ability,(59) but achieving this can necessitate the use of a range of interventions. This includes non-
drug interventions, for example, physical activity, heat/cold or physiotherapy. Additionally, drug 
therapies for MSDs may include topical or oral medication to ease joint pain and stiffness, and 
reduce inflammation. Amongst those severely affected, surgery may be required for people living in 
constant pain from arthritis, for example, osteoarthritis is responsible for over 90% of initial hip and 
knee joint replacements.(60,61)  
People with multiple long-term conditions are often required to carry out numerous tasks to 
maintain their health and administer their healthcare. This includes managing different tablets to be 
taken at specific times of day, or week, or only occasionally, keeping stock of their pills, creams, 
inhalers and injections, requesting repeat prescriptions on time, and visiting the pharmacy to collect 
items. Monitoring of treatment effectiveness with regular blood tests or physical tests (e.g. blood 
pressure measurement) may be required, and this may necessitate additional visits to the GP, or to 
the hospital, or may require an additional burden placed upon the individual (e.g. self-monitoring of 
blood glucose in diabetes mellitus).(56) As health systems are largely configured to treat individual 
diseases rather than support those living with multimorbidity,(30) managing multiple long-term 
conditions may require the attention of an array of separate health and care professionals at home, 
in the community and in hospitals. The time and effort required to remember and attend these 
appointments (including travel time and car parking or negotiating with hospital transport) 
contributes to the treatment burden.(56)  
Having a musculoskeletal condition as part of multimorbidity makes all of these activities more 
difficult. The Centres for Disease Control and Prevention’s (CDC) Arthritis Program in the USA has 
16 
 
identified nine functional limitations that people with arthritis report as being ‘very difficult’ or that 
they ‘cannot do,’ including grasping small objects, lifting or carrying, prolonged sitting or standing, 
walking ¼ mile, climbing stairs, and stooping, bending or kneeling.(62) As a result, comorbid arthritis 
or back pain substantially restrict the function and daily activities of people living with cardiovascular 
disease, diabetes and respiratory disease.(63) In addition, the unpredictable fluctuations in symptom 
severity that are a frequent feature of musculoskeletal disorders restrict mobility and can make 
attending hospital or GP appointments and planning ahead difficult, directly limiting people’s ability 
to manage their health.  
The personal expense of MSDs treatment should not be ignored either, as these costs may mean that 
a person with multiple long term conditions will not be able to afford all their own treatments, 
leading to deterioration in health. In the United States, osteoarthritis was found to contribute 
substantially to health care insurance expenditures, especially among women. Additional out-of-
pocket expenditures were also increased by $1,379 per annum in women and $694 per annum in 
men with osteoarthritis, a substantial personal cost.(64) Nearly half of people with arthritis surveyed 
by Arthritis Research UK, (48%) reported that they could not afford all the treatments they wanted or 
needed, and this figure increased to nearly eight out of 10 (78%) among those who stated that they 
were “struggling financially”.(49)  
Therefore, for a person who is just managing despite their multiple long-term conditions, developing 
arthritis can take away their ability to cope with, or afford, treatment. This may prevent effective 
self-management for other long-term conditions, which could then worsen. For example, people 
with painful osteoarthritis alongside their other long-term conditions have been shown to have 
increased risk of needing hospital admission.(65) Therefore, the onset of arthritis may be a “tipping 
point” for people with multimorbidity, depriving people of their ability to maintain their health and 
independence, leading to a spiral of decline. 
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MSDs contribute to the impact of multimorbidity on health and care services 
Management for people with multimorbidity should follow a person-centred, biopsychosocial 
approach incorporating the six desirable elements of care identified by people with long-term 
conditions (see Figure 4).(66) These elements can be enabled through systems to support self-
management and shared decision-making, and the implementation of care and support planning (see 
Table 1). However, these systems can be time and resource intensive because of the complexity of 
the care needed and are increasingly stretched because of the growing number of individuals who 
need such services. For example, UK health and social care costs average nearly £8,000 per year to 
care for a person living with three or more long-term conditions as compared with an estimated 
£3,000 for a person living with only one long-term condition.(2)  
The high prevalence and complexity of needs among people with MSDs is likely to contribute heavily 
to the overall cost of multimorbidity as MSDs carry their own innate burden on health and care 
services. The Ontario Health Survey, in Canada, found that musculoskeletal disorders were the 
reason for almost 20% of all health-care utilization(67). In 2015 alone, there were 98,211 primary hip 
replacements and nearly 104,695 primary knee replacements in England and Wales.(68) Across 
Europe, standardized incidences of hip fractures, requiring emergency surgery, vary but amount to 9 
to 11 per 10,000 person-years for the general population.(69) Also, since MSDs are usually life-long 
conditions, people with arthritis may need health and care services for many decades. In England, 
managing these conditions accounts for the fourth-largest National Health Service (NHS) programme 
budget of around £5.3 billion annually.(70) In the European Union, it is estimated that 2% of the total 
annual gross domestic product (GDP) is accounted for by the direct costs of musculoskeletal 
disorders.(71)  
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Figure 4: A narrative for person-centred coordinated care.(66)  
In English primary care, people with multimorbidity are frequent users of services(72): whilst six out 
of 10 (58%) patients have multimorbidity, they  account for almost eight out of 10 (78%) of the 
consultations in primary care.(11) People with multimorbidity average nine consultations each year 
compared to four consultations for those without.(11)  Musculoskeletal disorders contribute 
importantly to the healthcare burden since one in five of the general population consults their 
general practitioner (GP) about MSDs annually,(73) and MSDs account for one in eight (12%) of all 
appointments in primary care.(74) Similar estimated rates of consultation have also been reported in 
other countries, where 10-20% of primary care consultations are for MSDs.(75)   
The presence of multimorbidity also comes with an increased risk of hospitalization(76–78), and 
hospital outpatient visits(72). Once in hospital, people being treated for one condition may have 
other long-term conditions which directly impact on their health outcomes. For instance, the 
presence of co-morbidities increases the 30-day mortality risk of people following hip fracture 
surgery.(79) Osteoporosis leading to fragility fractures is the major cause of fractures, however, 
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incidence rates of fracture are influenced by falls-risk related co-morbidities such as heart disease, 
COPD, and dementia.(80) Therefore multimorbidity and MSDs, together, can magnify the total 
burden in secondary care.  
Table 1. Key management strategies for people with multimorbidity 
Supported self-
management 
National guidelines recommend that people living with multimorbidity should be 
supported to manage their own health and wellbeing, and given shared 
responsibility for this with their healthcare professionals.(81) A person’s ability 
to do this is affected by their symptoms, treatments, and the required 
administration to implement management. “Patient activation” is a measure of a 
person’s skill, knowledge, and confidence to manage their health and health 
care.(82) Low levels of activation have been linked to increased risk of 
hospitalization and use of emergency services.(83)  
Shared decision-
making support 
Shared decision-making is a process in which people can review all the treatment 
options available to them and participate actively with their healthcare 
professional in making that decision.(84) People living with multiple, long-term 
health conditions should be equal participants in decisions about their health 
and social care needs.(81) Decision aids can be used either before or during 
consultations to review options, helping the person and the health or care 
professional explore options.(85) Use of these aids improves how well informed 
and active in decision-making a patient feels, and gives a more accurate 
perception of risk.(86)  
Care and support Care and support planning comprises a collaborative, personalised care planning 
conversation usually occurring between a person with one or more long-term 
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planning conditions and a healthcare professional. UK guidelines recommend that this 
conversation should bring together information gathered by the healthcare 
professional and the goals, values, and priorities of the person with the 
condition, allowing time to develop and record a care and support plan.(81) This 
is also a multi-stage process so information such as test results can be shared in 
advance allowing the person time to consider their priorities, and to consult 
their family or carers if they wish.(87)  
 
MSDs contribute to the impact of multimorbidity in the workforce and the 
economy 
The physical limitations associated with MSDs have a widely acknowledged impact upon work: 
people with MSDs are less likely to be employed than people in good health, and are more likely to 
retire early.(88) In the European Union and the United States, musculoskeletal disorders are 
reported to account for a higher proportion of sickness absence from work than any other health 
condition.(21,89) In England, people with a musculoskeletal disorder have the third lowest rate of 
full-time paid work (see figure 5.) and are the third highest reported reason for being permanently 
sick or disabled, after mental health conditions or a recent cancer experience.(40) The indirect costs 
(inability to work, absenteeism, reduced productivity and informal care) of rheumatoid arthritis and 
osteoarthritis combined have been estimated at £14.8 billion each year.(90) According to another 
estimate, back pain is responsible for £10 billion of indirect costs to the economy each year.(91)  
Individually, musculoskeletal disorders and mental health problems are the two biggest causes of the 
greatest number of working days lost in England.(92) However, these types of conditions frequently 
occur together. For example, around three in 10 (32%) people of working age who have a 
musculoskeletal condition also have depression.(93) People with a comorbid mental health problem 
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alongside a musculoskeletal disorder are  less likely to be in work than those with musculoskeletal 
conditions alone.(93) 
 
Figure 5: Employment status by long-term condition among people 45-64 years of age in 
England.(40)  
Evidence on the impact of multimorbidity on work outcomes is scarce and often restricted to the 
study of two specific diseases combined.(5) However, the presence of multimorbidity, and number of 
chronic conditions, has been correlated with work absence(94–97) and reduced work productivity, 
also known as presenteeism.(94,95) The impact of multimorbidity on job status and work absence 
has also been shown to  incrementally worsen with each additional condition.(5)  
Importantly in multimorbidity, it has been shown that the type of long-term conditions, and not only 
number of long-term conditions, is associated with work outcomes.(95) Therefore, given the 
recognised effect of MSDs on work, it is likely that these conditions disproportionately contribute to 
the overall impact of multimorbidity upon work. To illustrate this, one study showed that the effect 
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of multimorbidity upon work disability, sickness leave and job status, is significantly amplified when 
MSDs are included in the definition of multimorbidity.(5) This suggests that MSDs should not be 
omitted from any studies examining, or adjusting for, the impact of multimorbidity in work 
participation.   
Implications for Practice and Policy 
The Chief Medical Officer for England has acknowledged osteoarthritis as ‘an unrecognised public 
health priority.’(98) People with arthritis have also drawn attention to the lack of recognition of their 
condition within healthcare services and across society.(49) This lack of recognition may be due to: a 
focus on conditions with higher mortality rates, rather than those which primarily increase morbidity 
and reduce quality of life; or the nihilistic perception that nothing can be done for people with 
musculoskeletal disorders and that arthritis is an inevitable part of ageing; or difficulties measuring 
musculoskeletal health outcomes, due to a lack of biomarkers or simple tests to monitor 
musculoskeletal health.  
Good musculoskeletal health underpins independent living with multiple long-term conditions. It 
must, therefore, firstly be recognised and addressed as part of multimorbidity. Musculoskeletal 
disorders negatively impact on quality of life,(40) functional ability,(63) risk of hospitalisation(77), 
and work disability(5) in multimorbidity. Metrics and tools developed for multimorbidity 
management programmes should therefore monitor outcomes that are relevant to musculoskeletal 
health, including pain and its impact, and functional ability. 
We suggest that high-quality data on musculoskeletal disorders and multimorbidity should be 
routinely obtained, published and used across public health, health and care and other related 
systems. These data should identify the scale and needs of people with multimorbidity and support 
service delivery and quality improvement activities. Currently, routinely-collected data sometimes 
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overlooks the co-existence of musculoskeletal disorders leading to substantial under-estimates of 
multimorbidity prevalence, let alone their impact. 
Local government and public health teams along with healthcare commissioners, payers and 
providers should identify, segment and understand the needs and requirements of people living with 
musculoskeletal disorders and multimorbidity in their population. They should identify barriers, 
including physical barriers that could limit the access of people with arthritis and musculoskeletal 
disorders to local programmes. To date, this has been poorly achieved, at least in England, for 
osteoarthritis and back pain.(99) 
People with multimorbidity should have access to person-centred, integrated services. For example 
care and support planning should be offered to anyone with a long-term condition,(100) but 
particularly to people with multimorbidity.(58) There must be clarity about who will be responsible 
for carrying out the different actions outlined in a plan, with appropriate support and coordination to 
link to local services.(101) When supporting people with multimorbidity to identify health goals, 
professionals should ensure that people have the information they need to make decisions about 
improving their musculoskeletal health. 
Public health information, programmes and campaigns should recognise and address the needs of 
the growing numbers of people living with multimorbidity and musculoskeletal disorders. The impact 
of pain and functional limitations on physical activity and independence should be taken into 
consideration when designing, implementing and evaluating public health information, programmes 
and campaigns.   
Disease-specific non-profit organisations and coalitions should recognise the prevalence of 
multimorbidity and work together to develop relevant resources, programmes, research and 
partnerships to meet the changing needs of their beneficiaries. Non-profit organisations should also 
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collaborate with service providers to identify ways of working that meet the needs of people living 
with multimorbidity, including: developing policy; providing information and support; and delivering 
models of care. In the UK, the non-profit sector is a substantial contributor to health and care 
support with nearly 36,000 health and social care organisations spending around £4,522 million 
directly supporting people, health systems or care systems in 2013/14.(102) This capacity should be 
harnessed to meet the needs of people with multimorbidity. 
Lastly, we suggest that funders must extend support for research to improve understanding of 
multimorbidity and to develop and evaluate strategies to meet the needs of people with 
multimorbidity. Organisations that historically have focussed on single disease areas should explore 
ways to collaborate on multimorbidity research. Facilitation for cross-sector collaborations can come 
from government funded research agencies such as the UK National Institute for Health Research 
(NIHR) which, in 2015, issued a research call for evaluation of interventions or services for older 
people with multimorbidity.(103) Examples of current multimorbidity research include the 3D study, 
which is developing and testing a comprehensive ‘3D’ health review every six months for people with 
multimorbidity in general practice;(104) and the HEAF study, which is measuring the impact of 
common health conditions and multimorbidity on work capability and work participation at older 
age.(105)  
Summary 
Musculoskeletal disorders such as arthritis or back pain are common and cause pain, stiffness, 
reduced mobility and dexterity, and depression. These symptoms affect every aspect of life: family, 
work and social.  
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It is now common for people to live with two or more long-term conditions. This multimorbidity 
reduces quality of life, worsens health outcomes and increases mortality. People with multimorbidity 
also rely more heavily on health and care services.  
People living with multimorbidity often have a musculoskeletal disorder as one of their health 
problems. Living well with multimorbidity involves a litany of complex tasks: monitoring symptoms, 
managing medications, coordinating carers and attending appointments. The pain and functional 
limitations associated with arthritis can make taking treatments, getting to appointments and co-
ordination of care harder. Therefore, the onset, or worsening, of arthritis or back pain can 
completely undermine people’s ability to cope with their health problems and manage their 
multimorbidity independently, leading to a precipitous deterioration in health and work-life.   
We believe that there is compelling evidence that policymakers, charities and research funders 
should recognise musculoskeletal health as part of multimorbidity. Consideration and assessment of 
pain and functional abilities should be included in tools and interventions to identify and support 
people with multimorbidity. Musculoskeletal health data should be captured and its quality 
improved; this information should be used in multimorbidity analyses and planning. Healthcare 
professionals should consider and discuss pain and functional limitations in their care and support 
planning conversations. Lastly, other professionals and the public should be educated to consider 
musculoskeletal health as part of multimorbidity through relevant public health resources.  
Practice points  
 Identification: Metrics and tools developed for multimorbidity management programmes 
should monitor and measure pain and its impact, functional abilities, and capability to 
manage. 
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 Data collection: National bodies should work together to ensure that data collection, 
analysis and publication raises awareness of multimorbidity and the relevance of its 
musculoskeletal component. 
 Planning and commissioning: Local planners and commissioners of health and care services 
should identify, segment and understand the needs and requirements of people living with 
musculoskeletal disorders and multimorbidity in their populations. This information should 
be collected and published where possible.  
 Care and support planning: Health and care professionals should ensure that people with 
multimorbidity can take part in a care and support planning process. This should use 
standardised tools to explore and record pain, functional limitations and how these affect 
daily activities. Other aspects of patient-centred care, such as shared decision making, should 
be an integral part of this process.  
 Health promotion: Public health organisations should ensure that their information, 
programmes and campaigns reflect and address the needs of the growing numbers of people 
living with multimorbidity including musculoskeletal disorders.  
 Voluntary sector: Disease-specific non-profit organisations and their respective coalitions 
should recognise that many people now live with multimorbidity and work together to 
develop resources, programmes, research and partnerships. This shared work should aim to 
meet the changing needs of people with multiple long-term conditions.  
27 
 
Research agenda 
 Prevalence: Robust surveillance systems should be developed and validated for monitoring 
multimorbidity prevalence, along with its component diseases, which should include 
musculoskeletal disorders.  
 Impact of multimorbidity: More data is needed to define the impact of multimorbidity, and 
its contributory diseases (including musculoskeletal disorders), on health, healthcare 
systems, society and work.  
 Models and pathways of care: Interventions, systems, and management strategies to 
support people with multimorbidity to live well should be designed, tested and scaled up.  
 Outcome measures: Standardised outcome measures should be developed, validated, 
implemented, analysed and interpreted for people with multimorbidity, including 
musculoskeletal disorders.  
 Individual perspectives: New research should seek to understand how the attitudes of 
people and health care professionals towards multimorbidity affect health outcomes.  
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